CYTO
Altamira Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · BM
$0.30
+0.00%Income statement
| Metric | TTM | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | (353.5K) | — | 305.6K | 63.9K | 174.5K |
| Cost of Revenue | 338.0K | — | 1.4M | 2.2M | — |
| Gross Profit | (691.7K) | — | (1.1M) | (2.2M) | 174.5K |
| Operating Expenses | |||||
| R&D Expense | 13.3M | 3.0M | 14.6M | 3.2M | 2.9M |
| SG&A Expense | 5.0M | 3.1M | 3.4M | 3.6M | 2.6M |
| General & Admin Expense | 3.5M | 3.1M | 3.4M | 3.6M | 2.6M |
| Selling & Marketing Expense | 2.5M | 15.3K | 15.7K | 39.9K | — |
| Other Expenses | — | — | 112.7K | 30.4K | (175.0K) |
| Total Operating Expenses | 14.1M | 6.5M | 18.0M | 6.9M | 5.3M |
| Cost and Expenses | 14.5M | 6.5M | 18.0M | 6.9M | 5.5M |
| Operating Income (EBIT) | (1.8M) | (5.9M) | (18.0M) | (5.3M) | (5.3M) |
| Non-Operating | |||||
| Interest Income | 946.0K | 730.2K | 114.3K | 27.0K | 258.00 |
| Interest Expense | 584.4K | — | 911.9K | 14.1K | 135.2K |
| Net Interest Income | 95.6K | 730.2K | (791.0K) | 12.9K | (135.0K) |
| Other Non-Op Income/Expense | (14.0M) | (1.4M) | (646.0K) | (1.5M) | (2.9M) |
| Non-Operating Income (excl Interest) | (172.0K) | — | (259.0K) | 1.5M | 2.8M |
| EBT (Pre-Tax Income) | (15.8M) | (7.3M) | (18.7M) | (6.8M) | (8.2M) |
| Income Tax Expense | 48.8K | — | (10.3K) | (117.9K) | (21.3K) |
| Bottom Line | |||||
| Net Income | (15.8M) | (7.3M) | (26.5M) | (17.1M) | (8.2M) |
| Earnings from Cont. Ops | (15.8M) | (7.3M) | (18.7M) | (6.7M) | (8.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (15.8M) | (7.3M) | (26.5M) | (17.1M) | (8.2M) |
| Per Share | |||||
| Basic EPS | ($228.63) | ($14.81) | ($582.58) | ($515.11) | ($545.41) |
| Diluted EPS | ($2,151.76) | ($14.80) | ($582.58) | ($515.11) | ($545.41) |
| Revenue Per Share | ($1.68) | $0.00 | $6.71 | $1.93 | $11.60 |
| Shares | |||||
| Basic Shares Outstanding | 209955 | 491000 | 45536 | 33116 | 15035 |
| Diluted Shares Outstanding | 209955 | 491258 | 45536 | 33116 | 15035 |
| Profitability Metrics | |||||
| EBITDA | 2.0M | (1.4M) | (17.6M) | (6.7M) | (8.1M) |
| D&A | 4.6M | 5.9M | 118.9K | 76.4K | 20.0K |
| EBIT | 678.0K | — | (17.8M) | (6.8M) | (8.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2023